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doi:10.1016/j.ejvs.2009.12.012Abstract Objective: A challenge facing clinicians is identifying patients with asymptomatic
carotid disease at risk of plaque instability. We hypothesise that locally released angiogenic
growth factors contribute to plaque instability.
Methods: Carotid endarterectomy specimens from eight symptomatic and eight asymptom-
atic patients were interrogated for microvessel density and angiogenic growth factor expres-
sion histologically using immunofluorescence, and biochemically using quantitative real-time
polymerase chain reaction (q-RT-PCR). Bio-Plex suspension array was used to assess circu-
lating biomarkers in venous blood from the same patients and six healthy age-matched
controls.
Results: Immunofluorescence demonstrated significantly greater neovessel density in symp-
tomatic plaques (PZ 0.010) with elevated expression of hepatocyte growth factor (HGF)
(PZ 0.001) and its receptor MET (PZ 0.011) than in asymptomatic plaques. The q-RT-PCR
demonstrated up-regulation of Endoglin (CD105), HGF (PZ 0.001) and MET (PZ 0.011) in
the plaques of symptomatic versus asymptomatic patients. Bio-Plex suspension array
demonstrated elevated HGF (PZ 0.002) serum levels in symptomatic versus asymptomatic
patients and healthy controls, and decreased platelet-derived growth factor (PDGF)
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A Comparative Study of Carotid Atherosclerotic Plaque Microvessel Density 389Conclusion: Plaque instability may be mediated by HGF-induced formation of new microves-
sels, and decreased vessel stability resulting from decreased PDGF. Suspension array tech-
nology has the potential to identify circulating biomarkers that correlate with plaque
rupture risk.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Table 1 Patient demographics.
Risk factor/group Symptomatic
(nZ 8)
Asymptomatic
(nZ 8)
Age, median (range) 66 (61e71) 68 (67e76)
Sex, male: female 6:2 5:3
Smoking, n (%) 7 (88%) 5 (63%)
Statin use, n (%) 8 (100%) 8 (100%)
Symptoms e TIA, n (%) 7 (88%) e
Amaurosis fugax, n (%) 1 (12%) e
Diabetes, n (%) 5 (63%) 4 (50%)
All values P> 0.05 between both groups, except the variable
group (patient symptomatology).Stroke is the third most common cause of death in the
Western world and a major economic and resource burden.1
An important cause of stroke is the transformation of
a quiescent carotid artery atherosclerotic lesion into an
unstable morphology, which becomes vulnerable to rupture
and thrombo-embolism.
Carotid endarterectomy is established for preventing
future strokes in patients with symptomatic and, to a lesser
extent, asymptomatic disease.2 A challenge facing vascular
specialists is differentiating patients with asymptomatic
carotid disease who are at risk from plaque instability.
Identifying such patients would reduce the number of
unnecessary surgical procedures being performed. However,
to date, there are no clinically validated biomarkers to
predict asymptomatic patients at the risk of stroke. Identi-
fication of biomarker signatures associated with plaque
instability may allow for a more precise patient-selection
strategy for carotid surgery, in the presence of significant but
asymptomatic disease.
An important component of atherogenesis is the formation
of newmicrovessels within the diseased vessel wall, a process
known as neovascularisation. A multitude of pro-angiogenic
factors2 has been implicated in this process, including hepa-
tocyte growth factor (HGF ).3 HGF, a mesenchyme-derived
pleiotrophic cytokine initially recognised as a potent mitogen
for hepatocytes,4 is now acknowledged to have strong mito-
genic andmorphogenic effects on various cell types, including
endothelial cells (ECs) and smooth muscle cells (SMCs).5e7
HGF functions by binding to its corresponding receptor, MET,
a member of the tyrosine kinase family.
This study investigates the hypothesis that symptomatic
carotid plaques are associated with increased plaque
microvessel density as comparedwith asymptomatic lesions.
We postulate that these microvessels are correlated to
localised expression and systemic levels of pro-angiogenic
growth factors and associated receptors, in particular, HGF
and MET. The aims of the study are to (1) identify and
quantify microvessels in human atherosclerotic plaques
obtained from symptomatic versus asymptomatic patients
undergoing carotid endarterectomy; (2) establish the levels
of gene expression of HGF and MET; and (3) elucidate
whether HGF or any other angiogenic growth factors are
differentially modulated in symptomatic or asymptomatic
disease, thus lending credence to their suitability as poten-
tial biomarkers in human serum, whichmay identify patients
at risk from plaque instability.
Materials and methods
Tissue collection and sectioning
Carotid plaques from eight symptomatic and eight
asymptomatic patients were analysed for this preliminarystudy. For Bio-Plex analysis, serum from these patients
was compared against that of six healthy age-matched
controls.
Local Research Ethics Committee approval was granted
for the use of human carotid plaques and serum for this
study (08/H1014/88). Carotid atherosclerosis specimens
were obtained from patients undergoing carotid endarter-
ectomy for 70% internal carotid artery stenoses. Prior to
surgery, patients were consented and assessed with respect
to age, sex, co-morbidity and symptomatology (Table 1). All
patients enrolled on this study were on anti-platelet and
HMG-CoA reductase inhibitor therapy. The surgical proce-
dures were performed using a standardised technique
under general anaesthesia.
All plaques were processed at the time of surgery. After
removal, the plaque was divided into three sections; one
washed in phosphate-buffered saline (PBS) and fixed in 4%
paraformaldehyde and processed for paraffin embedding,
the second fixed in OCT embedding medium and frozen at
80 C and the third put into RNALater (Applied Bio-
systems, Foster City, CA, USA) for RNA analysis. Formalin-
fixed, paraffin-embedded sections were used to confirm
the gross morphology of the plaque by preparing 7 mm
haematoxylin and eosin-stained sections. A panel of
archived internal mammary arterial sections was used as
non-atherosclerotic controls, which were obtained from
arterial segments surplus to requirements from coronary
artery bypass graft (CABG) surgery and previously
described.8
Quantitative real-time polymerase chain reaction
(q-RT-PCR)
RNA extraction and cDNA synthesis
RNA extraction was carried out by homogenisation of the
tissue sample using a Hybaid RiboLyser Cell Disrupter.
Tissue was dissolved in 1 ml of TRIzol (Invitrogen,
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bead tube (MP Biomedicals Cat # 6913-100, Solon, OH,
USA). The tissue solution was ribolysed for two cycles of
20 s. The homogenised sample was incubated for 5 min at
22 C to permit complete dissociation of nucleoprotein
complexes. Then, 0.2 ml of choloform per 1 ml of TRIzol
was added, centrifuged at 12 000 g for 15 min at 5 C.
Following the centrifugation, the mixture separated and
the aqueous colourless phase containing the RNA was
transferred to a fresh tube, mixed with 0.5 ml of isopropyl
alcohol and centrifuged at 12 000 g for 10 min at 5 C.
The supernatant was removed, preserving the RNA pellet,
which was washed with 75% ethanol, centrifuged at
7500 g for 5 min at 5 C. The resulting RNA pellet was
air-dried for 5 min and re-dissolved in 20 ml of RNAase-free
water, with subsequent DNAase treatment.
Complementary DNA (cDNA) was synthesised from 1 mg
of total RNA using a reaction mix with a final volume of
20 ml: 4 ml of 5 buffer, 1 ml of oligo(dT)15 primer
(100 pmol ml1), 2 ml of dNTP (10 mM), 0.5 ml of RNAase
inhibitor, 0.4 ml of AMV RT enzyme (Roche, Basel,
Switzerland) and diethylpyrocarbonate (DEPC)-treated H2O
adjusted to the volume of 20 ml. The reaction was per-
formed at 42 C for 1 h to produce cDNA.
Q-RT-PCR
Confirmation that the samples expressed Endoglin (CD105),
HGF and MET was achieved using SYBR Green real-time
PCR. PCR primer sequences were designed using design
software (Primer Express ver. 2.0.0, Applied Biosystems)
(Table 2). BLAST (Basic Local Alignment Search Tool)
searches were performed for all primer sequences to
confirm gene specificity. The q-RT-PCR assays were per-
formed using the 7900HT Fast Real-Time PCR System
(Applied Biosytems) in a 96-well plate format. Real-time
data were analysed using the Sequence Detection System
2.2.1 software (v20040907-2, 2004, Applied Biosystems,
Foster City, CA, USA) with the detection threshold set
manually at 0.05 for all the assays. All transcripts were
standardised to Actb (b-actin) (housekeeping gene).
Quantification of relative gene expression was calculated
by the comparative Ct method (2DDCt).9Table 2 Primers for quantitative RT-PCR.
Gene of interest Accession number Primer positiona
HGF NM_000601 F982
R1032
MET NM_000245 F5006
R5056
Endoglin NM_000118 F1530
R1580
ACTB NM_001101 F3255
R3305
Forward and reverse primers for PCRs. BLAST (Basic Local Alignment S
confirm gene specificity. All primers were synthesised from SIGMAeA
a Refers to position from the transcription start site within the
respectively.Immunohistochemistry and immunofluorescence
Immunohistochemistry was used for primary antibody
staining. Immunofluorescence was used for endothelial cell
localisation and quantification. For immunohistochemistry,
frozen sections were cut at 6 mm on the cryostat and fixed
in pre-cooled 100% acetone for 10 min. The serial sections
were permeabilised using 0.1% Triton x-100 in PBS. Endog-
enous peroxide activity was blocked using 0.3% hydrogen
peroxide in methanol for 20 min at 4 C. The blocking serum
was applied to each sample (100 ml) and was kept at 22 C
for 1 h. A negative control was set up for each slide (the
sample was treated with non-immune, non-specific anti-
bodies), primary antibody HGFa, (1:50, H-145 sc-7949, Lot
#L0804, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
MET C-28, (1:20, sc-161, Lot #H2206, Santa Cruz Biotech-
nology), CD31, (1:30, Cat No M0823, DakoCytomation,
Glostrup, Denmark), smooth muscle a-Actin, (1:400 A5228,
DakoCytomation) was placed on the sample for 1 h at 22 C.
The samples were then washed in PBS, and incubated for
1 h at 22 C with the corresponding horseradish peroxidise
(HRP)-conjugated secondary antibody. The samples were
then treated with 3,30-diaminobenzidine tablets (Sigma
Fast D-4168, DAB peroxidise substrate, SigmaeAldrich
Co., USA) until a colour change was noted. The reaction was
then stopped, slides were washed in PBS, counterstained
with Mayer’s haematoxylin (H) and mounted with mounting
medium (Vector Laboratories, Burlingame, CA, USA).
For immunofluorescence, serial frozen sections were
exposed to 5 mgml1 fluorescein-labelled UEA-I (Ulex
Europaeus Agglutinin-1) (Vector Laboratories, Burlingame,
CA, USA) diluted 1:50 in water for 2 min. The sections were
rinsed in PBS for 2 min, sequentially dehydrated (70%
ethanol for 30 s, 95% ethanol for 30 s and 100% ethanol for
1 min). Sections were counterstained with 40e60diamidino-
2-phenylindole (DAPI) to localise the nuclei of all cell types,
adding further distinction to any positively stained micro-
vessels. The slides were air-dried for 2 min and immediately
mounted using VECTASHIELD fluorescence mounting media
(H-1000, 10 ml, Vector Laboratories, Burlingame, CA, USA).
All slides were viewed under a Leica colour/fluorescent
microscope (DFC320/DFC 350FX). Images were capturedForward primers (50/ 30) Reverse primers (50/ 30)
ACTCTTGACCCTCACACCCG AGCGCATGTTTTAATTGCACAG
CACCATCCCCGGCTAATTT ATGGCAAAACCCCGTCTCTA
TGTGAGGCAGAGGACAGGG GGAGTAAGCACTGCGCAAGAC
GGACATGGAGAAGATGTG CATCTCCTGCTCGAAGTC
earch Tool) searches were performed for all primer sequences to
LDRICH Company Ltd., Dorset, UK.
gene sequence. F&R refers to forward and reverse orientation
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2003e2007, Leica Microsystems, Switzerland, Ltd., CMS
GmbH). Images using different fluorescent wavelengths
were then merged.
Bio-plex suspension array
The Bio-Plex/Luminex Bead array (Bio-Rad Laboratories
Ltd., CA, USA) was used to analyse serum concentration of
angiogenic factors in patients’ venous blood including
angiopoietin 2, follistatin, granulocyte-colony stimulating
factor (GCSF), HGF, interleukin (IL)-8, leptin, platelet-
derived growth factor-BB (PDGF-BB), PCAM1 and vascular
endothelial growth factor (VEGF) (Bio-Rad’s ‘Pro-Human
Angiogenic 9-plex plate’ Cat No: #171A4S11M).
Collection of serum samples
The 10 ml of venous blood withdrawn aseptically into sterile
heparinised tubes was taken preoperatively and centrifuged
at 3200 rpm for 15 min at 4 C. The resulting clear serumwas
stored at 20 C in aliquots until needed for analysis.
Bio-Plex luminex immunoassay
Levels of nine angiogenic analytes, including HGF, were
analysed in patient serum using Bio-Plex immunoassay
(Bio-Rad) according to the manufacturer’s instructions.
A standard dilution series was made. All samples were
compared against normal human serum samples (control).
Bio-Plex Pro angiogenesis data acquisition
Data were analysed using Bio-Plex Manager software
version 5.0. The plate format included bead region data for
each analyte, as well as dilution factors for both the
controls and standards. Data acquisition was specified for
100 beads per region. The bead map was set to 25 per
region, and the sample size was set to 50 ml. Default DD
gate values were set to 5000 (low) and 32 000 (high).
Statistical analysis
The ManneWhitney U-test was used to compare the groups.
This non-parametric method was used because the
measurements of the angiogenic factors were not normally
distributed. Values of P< 0.05 were considered significant
(SPSS Inc., v16.0, Chicago, IL, USA).Figure 1 Characterisation of microvessels in carotid plaques
microvessels from carotid samples using fluorescein-labelled UEA-
stained green enabling identification of microvessels (white arro
luminescence by counterstaining sections with DAPI which detecte
merged in (C) (BarZ 50 mm).Results
Immunohistochemistry analysis
Microvessel density quantification
The average carotid cross-sectional area for both symp-
tomatic and asymptomatic plaques was 15 mm2 and 10
sections from each block were examined. Fig. 1 shows
a microvessel at high power (40). Microvessels were
counted from five random fields of view (2.25 mm2 per
section) and 45 mm2 was examined within each plaque and
the average was calculated. The median neovessel density
(vessels mm2) was higher in symptomatic plaques than
asymptomatic plaques (8 (range 3e16) vs. 3 (range 0e7);
PZ 0.010) plaques (Fig. 2).
Localisation of a-SMA
Neovessels themselves can often be characterised as
‘mature’ or ‘immature’. The latter have not acquired the
coating of smooth muscle cells associated with mature
vessels. Immunostaining of a-SMA revealed a coating of
some microvessels in the plaques, in addition to the pres-
ence of irregular, diffuse staining (Fig. 3). These smooth
muscle cells appeared to have lost their morphological
integrity that occurs within a normal medial layer.
Molecular analysis of HGF/MET expression
Modulation of gene expression within plaque specimens
The q-RT-PCR analysis of HGF and MET revealed a 4.7- and
2.8-fold mRNA expression increase, respectively, in symp-
tomatic versus asymptomatic plaques (PZ 0.001,PZ 0.011,
respectively, Fig. 4). Although there was 1.8-fold increase in
Endoglin mRNA expression in symptomatic versus asymp-
tomatic plaques, this did not reach statistical significance
(PZ 0.184).
Localisation of HGF/MET protein
Localisation of HGF protein
Using HGF antibodies, immunohistochemistry was per-
formed on both cryosections and paraffin-fixed sections of
human carotid atherosclerotic plaques. Some of the regions
within the plaques contained endothelial cells that were
positive for HGF immunoreactivity. This was achieved by(UEA-I) Representative micrograph showing identification of
I (Ulex Europaeus Agglutinin-I) staining. The endothelial cells
ws A & C). Microvessels were distinguished from background
d nuclear staining of all cells in the vessel wall (B). Images are
Figure 2 Number of microvessels identified from plaques of
symptomatic and asymptomatic patients. Microvessels were
identified in 5 fields of view within each section. Ten sections
were quantified from each patient block. 8 symptomatic pla-
ques were compared against 8 asymptomatic plaques. Statis-
tical analysis using ManneWhitney U-test (PZ 0.01).
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marker, CD31 (Fig. 5). HGF-positive stains were found
consistently in all sections. However, HGF staining was not
detected in the non-atherosclerotic internal mammary
arterial sections.10
Localisation of MET
Immunostaining for MET was positive in both symptomatic
and asymptomatic plaques. The MET positive cells also
appear to demonstrate a-smooth muscle positive staining.
This supports and extends our previous findings, where we
demonstrated the presence of MET in human tibial arterial
atherosclerotic lesions.11
Analysis of potential serum markers of disease
Serum angiogenesis factors in symptomatic versus
asymptomatic patients
The serum concentration of nine angiogenic growth
factors was evaluated (Fig. 6): angiopoietin 2, follistatin,Figure 3 Characterisation of smooth muscle actin in carotid
plaques (aSMA) Morphology of smooth muscle actin coverage
within human carotid atherosclerotic plaques. In addition to
clear microvessel presence (black arrows), there was also
diffuse, poorly organised positive smooth muscle cell staining
(red arrows) (BarZ 50 mm).GCSF, HGF, IL-8, leptin, PDGF-BB, PECAM1 and VEGF. HGF
showed a statistically significant elevation in the serum of
subjects with symptomatic carotid disease than in their
asymptomatic counterparts and healthy controls (HGF:
1033 pg ml1 (952e2538) vs. 78.9 pg ml1 (46.5e113),
respectively; pZ 0.002), while PDGF (PDGF-BB:
531 pg ml1 (429e655) vs. 1097 pg ml1 (986e1674);
pZ 0.036) was significantly reduced in symptomatic
when compared with asymptomatic patients. There was
no statistical significance with the other angiogenic
factors in the serum of subjects with symptomatic carotid
disease compared with their asymptomatic counterparts
(Table 3).Discussion
Several studies have linked serum levels of HGF with
vascular disease, and we have previously reported MET
positive SMCs in human tibial artery atherosclerotic
lesions.11 This study has localised and quantified HGF gene
expression in symptomatic and asymptomatic human
carotid plaques by molecular techniques. Given that HGF
regulates endothelial cell growth, apoptosis and angiogen-
esis, its presence in plaques could contribute to the path-
ogenesis of atherosclerosis.
In this preliminary study, the aim was to determine
whether changes in systemic levels and local expression of
HGF could correlate to patient symptomatology. This was
achieved using a number of approaches: localisation of
this pro-angiogenic growth factor by standard immuno-
histochemistry techniques, a quantitative analysis by
q-RT-PCR and a systemic protein serum screen by Bio-
Plex suspension array technology. Our findings have
shown the localisation of HGF and its biological receptor,
MET, in carotid plaques. The q-RT-PCR analysis has
revealed a significantly higher expression of HGF in
symptomatic versus asymptomatic patients. Bio-Plex
suspension array has also confirmed an increase in serum
HGF levels, in addition to the elevated localised expres-
sion amongst the symptomatic cohort.
Angiogenesis has been shown in symptomatic carotid
plaques. McCarthy et al.12 and Mofidi et al.13 demon-
strated a strong association between an increased number
of new vessels within symptomatic carotid plaques and
stroke. It was postulated that plaque angiogenesis may be
significant in the development of symptomatology. The
present study supports this observation, whilst at the
same time reveals that the increased neovascularisation,
in symptomatic plaques, is associated with increased HGF
and MET gene expression.
The increased microvessels in the plaque of unstable
lesions could act as a source of activated endothelial
cells; cells that are vital for leucocyte adhesion
and activation.13 Infiltration of leucocytes and other
inflammatory cells results in release of proteases, most
notably of the matrix metalloproteinase family, which
cause plaque disruption.13 The morphological nature of
the ‘immature’ neovessels may lend themselves to
rupture more easily than their mature and stable coun-
terparts, creating an escalating pro-inflammatory
microenvironment.
Figure 4 HGF and c-Met mRNA expressions detected by q-RT-PCR. Statistical analysis compares DDCt values, for each gene of
interest. 8 symptomatic plaques were compared against 8 asymptomatic plaques. Statistical analysis using ManneWhitney U-test.
HGF (PZ 0.001) c-Met (PZ 0.011).
Figure 5 Localisation of HGF within human carotid plaques HGF was characterised within microvessels (black arrows - left). This
was achieved by serial section staining (right), using CD31 as an endothelial cell marker. Sections were counterstained with
Haematoxylin (BarZ 50 mm).
Figure 6 j Bio-Plex angiogenesis serum analyte levels in
symptomatic, asymptomatic and healthy control patients.
Serum harvested from patients and subjected to Bio-Plex
suspension array analysis. 8 symptomatic and 8 asymtpomatic
patients were compared against 6 healthy matched controls.
Statistical analysis using ManneWhitney U-test. HGF
* (PZ 0.002). PDGF ** (PZ 0.036).
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Analysis of patient serum did reveal a significantly lower
level of PDGF in symptomatic compared with asymptom-
atic patients. Angiogenesis not only depends on endo-
thelial cell invasion and proliferation; it also requires
mural cell coverage of vascular sprouts for vessel stabili-
sation.14 These processes are coordinated by many
factors, including PDGF and its receptor, which affects
vascular smooth muscle cells (VSMCs). After PDGF
receptor blockade in mouse models, Greenberg et al.15
observed suppression of angiogenesis in the absence of
PDGF, consistent with a role of PDGF in the release of pro-
angiogenic factors and the lack of mural cell recruit-
ment.16 Greenberg et al. go on to comment that exclusive
PDGF treatment results in a robust influx of alpha-smooth
muscle actin-expressing cells being recruited to the
surface of patent blood vessels.17
In light of these studies, one can postulate that the
decreased levels of PDGF in symptomatic patients when
compared with asymptomatic patients may play a role in
vessel stabilisation. The lower levels in symptomatic
patients may impair or restrict the extent of SMA recruit-
ment to the neovessels in the plaque, leading to an
increased number of ‘leaky’ vessels, and more extensive
plaque instability. However, serum levels of PDGF in
symptomatic subjects are similar to levels of PDGF in the
healthy controls; there was no significant difference
Table 3 Serum angiogenesis factors in symptomatic versus asymptomatic patients.
Analyte Symptomatic e pg/ml (range) Asymptomatic e pg/ml (range) P value
Angiopoeitin-2 47.1 (38.1e73.5) 58.1 (35.8e67.4) 0.770
Follistatin 143 (195e309) 51.5 (43.8e165) 0.078
GCSF 26.6 (19.5e75.8) 15.4 (11.4e40.8) 0.770
HGF 1033 (952e2538) 78.9 (46.5e113) 0.002*
IL-8 116 (70.5e212) 19.5 (12.4e74.9) 0.599
Leptin 529 (471e654) 286 (257e346) 0.262
VEGF 48.6 (14.8e54.5) 112 (94.6e196) 0.133
PECAM-1 46.2 (36.4e79.7) 26.6 (15.4e97.1) 0.170
PDGF 531 (429e655) 1097 (986e1674) 0.036*
Serum harvested from patients and subjected to Bio-Plex suspension array analysis. Values are median, the range in parenthesis.
Statistical analysis using ManneWhitney U-test. Significant values are indicated by *.
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be mediated by more complex mechanisms and play a more
influential role in the diseased state.
HGF in the atherosclerotic plaque
The data in this study demonstrate the presence of HGF in
atherosclerotic lesions compared with no detection in the
non-atherosclerotic controls, suggesting that HGF may
participate in this disease process.
The invasiveness of monocytes is stimulated by HGF
treatment, implicating a role for HGF in monocyte
recruitment.18 Furthermore, interactions between VSMCs
and monocytes result in HGF production from both cell
types, which could perpetuate the inflammatory
response.19 As HGF is a potent angiogenic factor, its
presence in atherosclerotic lesions could aid neo-
vascularisation within the plaque. The data presented
demonstrate HGF staining in association with neo-
vascularised areas within the plaque. Angiogenesis and
migration of endothelial cells through the extracellular
matrix requires degradation of the matrix, which can be
accomplished by matrix metalloproteinases that also can
be induced by HGF.20
Clinical impact
In the context of carotid atherosclerotic plaques,
perhaps a more profound understanding of plaque
stability will help ensure an improved and specific
patient-selection strategy for interventional therapies.
Suspension array technology has great potential for the
identification of circulating biomarkers that may corre-
late with angiogenesis and plaque rupture risk. HGF
itself may even be used as a biomarker to screen
asymptomatic patients with moderate carotid disease.
Another possible target is to question whether the pla-
que stabilisation could be achieved by local therapies.
Local delivery of anti-angiogenic agents has met with
recent clinical success in the treatment of age-related
macular degeneration.21 To limit potential systemic side-
effects of any therapeutic agents, stent- or catheter-
based therapies may be an effective means of localised
drug delivery to eliminate neovascularisation in a clinicalsetting. A recent experimental study22 with arterial
atherosclerotic plaques has shown that stent-based
delivery of anti-angiogenic agents may be a viable
treatment option.
Limitations of the study
Although the data presented have proposed potentially
novel screening biomarkers for carotid disease, the study
itself has limitations. Patient numbers were small and
should be considered a limiting factor in the analysis. It
should, therefore, be emphasised that this study is
preliminary in nature. In addition to this, future studies
should also correlate serum biomarker levels with the
degree of symptoms and samples should also be taken
postoperatively.
Conclusion
These data show a significantly increased microvessel
density and expression of HGF and MET in symptomatic
plaques in comparison to their asymptomatic counterparts.
The transition from a stable to an active plaque may thus
be partly mediated by an increased expression of these
angiogenic factors.
Expression of HGF in the carotid plaques amongst
symptomatic patients, with q-RT-PCR, was correlated with
increased systemic HGF levels in these patients. Suspension
array analysis revealed a significantly higher concentration
of HGF in symptomatic patients, when compared with
asymptomatic and healthy controls. Levels of PDGF were
found to be significantly lower in symptomatic than in
asymptomatic patients.
The evidence provided suggests that HGF appears to
promote the progression of carotid atherosclerotic plaques.
However, the presence of cytokines and many other growth
factors may affect the endothelial response to HGF. This
study may ultimately indicate new interventional therapies
for the prevention of plaque formation, possibly by targeting
neovascularisation via the HGF/MET signalling pathway.
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